Live
Home·Deals·Biotech·Amgen acquires Dark Blue Therapeutics
Amgen acquires Dark Blue Therapeutics (2026)
SEO URLwww.firestrike.ai/deals/dark-blue-therapeutics-amgen-acquisition-2026-4
acquisitionAnnounced · Jan 7, 2026BiotechSource · CredibleArticle · Factual
Dark Blue Therapeutics
Amgen
Dark Blue Therapeutics · Amgen

Amgen acquires Dark Blue Therapeutics

David Najork
David Najork · Founding Software Engineer
Published · Updated · 1 min read
ShareXLinkedInEmail
Deal value
$840M
Target
Dark Blue Therapeutics
Dark Blue Therapeutics
Acquirer
Amgen
Amgen
Full Acquisition
Status
Completed

Amgen agreed to acquire Dark Blue Therapeutics. Reported deal value: $840M. Status: Completed. Sector: Biotech. Target headquarters context: Location not specified.

This page summarizes publicly available information about the transaction as of 2026-01-07. Figures and status may change as filings and press coverage update.

In today Pharmaceutical Executive Daily, Amgen announces an $ 840 million acquisition of Dark Blue Therapeutics , GSK enters a multi-year precision medicine collaboration with Helix, and industry leaders examine how workable operating models are reshaping cell and gene therapy commercialization

Deal timeline

Announced
Jan 7, 2026 · pharmexec.com
Additional milestones (proxy, vote, close) appear as filings and press updates are indexed.
Sector context

This transaction is classified in Biotech with a reported deal value of $840M. Figures and status may change as sources update.

Sources: pharmexec.com · Primary article · FireStrike proprietary index